-
Product Insights
NewLikelihood of Approval Analysis for Warts
Overview How likely is it that the drugs in Warts will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Warts Overview Warts, caused by the human papillomavirus (HPV), are common skin growths...
-
Product Insights
NewLikelihood of Approval Analysis for Varicella Zoster (HHV-3) Infections
Overview How likely is it that the drugs in Varicella Zoster (HHV-3) Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varicella Zoster (HHV-3) Infections Overview Varicella-zoster virus (VZV), also known...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VENT-03 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VENT-03 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VENT-03 in Systemic Lupus Erythematosus Drug Details: VNX-01 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VENT-03 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VENT-03 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VENT-03 in Systemic Sclerosis (Scleroderma) Drug Details: VNX-01 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VENT-03 in Dermatomyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VENT-03 in Dermatomyositis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VENT-03 in Dermatomyositis Drug Details: VNX-01 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VENT-03 in Neuroinflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VENT-03 in Neuroinflammation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VENT-03 in Neuroinflammation Drug Details: VNX-01 is under development for the treatment of...
-
Thematic Analysis
NewCybersecurity – Thematic Intelligence
The cybersecurity industry faces a challenge that is anything but business as usual. The prospect of offensive attacks using artificial intelligence (AI) is prompting increases in cybersecurity budgets as organizations try to understand the impact of generative AI on their security. Hacking groups will likely use large language models (LLMs) trained on malware to target their attacks more effectively. AI is already used for threat detection, and its greater adoption will help offset attacks. However, learning how to counter AI-led...
-
Sector Analysis
New Zealand Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to 2028
New Zealand Construction Market Report Overview The New Zealand construction market size was $56.3 billion in 2023. The market will achieve an AAGR of 3% during 2025-2028. The growth is attributed to the rising investment in transport, energy, housing, health, and education infrastructure projects. New Zealand Construction Market Outlook, 2023-2028 ($ Billion) Buy the Full Report to Know More about the New Zealand Construction Market Forecast Download a Free Report Sample The New Zealand construction market research report offers a...
-
Product Insights
Sicca Syndrome (Sjogren) – Drugs In Development, 2023
Global Markets Direct’s, ‘Sicca Syndrome (Sjogren) - Drugs In Development, 2023’, provides an overview of the Sicca Syndrome (Sjogren) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...